Skip to main content
SpringerLink
Log in

Antirheumatika und Antiphlogistika

  • Chapter
Arzneiverordnungs- Report 2014

  • 1530 Accesses

Zusammenfassung

Bei den Verordnungen der Antirheumatika und Antiphlogistika dominieren auch 2013 mit klarem Abstand die nichtsteroidalen Antiphlogistika. Unter diesen steht Ibuprofen weiterhin an erster Stelle vor Diclofenac in der Verordnungshäufigkeit. Die Verordnungen der zwei auf dem Markt verbliebenen selektiven Cyclooxygenase- 2-Hemmer sind erneut gegenüber dem Vorjahr angestiegen. Insgesamt machen die COX-2-Hemmstoffe auch 2013 jedoch nur gut 10% der Gesamtverordnungen in diesem Indikationsgebiet aus.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2004): „Aus der UAW-Datenbank“: Kardiovaskuläre Nebenwirkungen sind ein Klasseneffekt aller Coxibe: Konsequenzen für ihre künftige Verordnung. Dtsch Ärztebl 101: A 3365

    Google Scholar 

  • Bannwarth B, Richez C (2011): Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 10: 123–131

    Article  PubMed  Google Scholar 

  • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528

    Article  PubMed  Google Scholar 

  • Brater DC, Harris C, Redfern JS, Gertz BJ (2001): Renal effects of COX-2 selective inhibitors. Am J Nephrol 21: 1–15

    Article  PubMed  Google Scholar 

  • Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102

    Google Scholar 

  • Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D et al (2001): Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech 53: 343–353

    Article  PubMed  Google Scholar 

  • Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, Van Der Heijde D, Erdmann E, Laine L (2006): Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368: 1771–1781

    Article  PubMed  Google Scholar 

  • Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002): Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110

    Article  PubMed  Google Scholar 

  • Charatan F (2002): Arthritis drug should be removed from market, says consumer group. Brit Med J 324: 86–9

    Article  Google Scholar 

  • Cryer B, Feldman M (1998): Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413–421

    Article  PubMed  Google Scholar 

  • Day R (2002): Another selective COX-2 inhibitor: more questions than answers? J Rheumatol 29: 1581–1582

    PubMed  Google Scholar 

  • DeAngelis CD, Fontanarosa PB (2008): Impugning the integrity of medical science. The adverse effects of industry influence. JAMA 299: 1833–1835

    PubMed  Google Scholar 

  • DeWitt DL (1999): Cox-2-selective inhibitors: the new super aspirins. Mol Pharmacol 55: 625–631

    PubMed  Google Scholar 

  • Dreser H (1899): Pharmakologisches über Aspirin (Acetylsalicylsaüre). PflÜgers Arch 76: 306–318

    Article  Google Scholar 

  • Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H et al (1999): Celecoxib versus diclofenac in long term management of rheumatoid arthritis: randomized double blind comparison. Lancet 354: 2106–2111

    PubMed  Google Scholar 

  • Eras J, Perazella MA (2001): NSAIDs and the kidney revistied: are selective cyclooxygenase-2 inhibitors safe? Am J Med Sci 321: 181–190

    Article  PubMed  Google Scholar 

  • European Medicines Agency (2005): Public Statement. European Medicines Agency announces regulatory action on COX-2 inhibitors. Publiziert am 17. Februar 2005 unter: www.emea.eu.int/htms/hotpress/d6275705.htm

    Google Scholar 

  • European Medicines Agency (2007): Press release. European Medicines Agency recommends restricted use for piroxicam. Publiziert am 25. Juni 2007 unter: www.emea.europa.eu/pdfs/human/press/pr/26514407en.pdf

    Google Scholar 

  • European Medicines Agency (2012): European Medicines Agency finalises review of recent published data on cardiovascular safety of NSAIDs. Press release 19.1–0.2012

    Google Scholar 

  • FDA Alert for Healthcare Professionals (2005): Valdecoxib (marketed as Bextra). Publiziert am 7. April 2005 unter: www.fda.gov/bbs/topics/news/2005/NEW01171.html

    Google Scholar 

  • FDA-Statement (2004): FDA-Statement on Naproxen. Publiziert am 20. Dezember 2004 unter: www.fda.gov/bbs/topics/news/2004/new01148.html

  • Food and Drug Administration (2004): FDA Public Health Advisory: Safety of Vioxx. Publiziert am 30. September 2004 unter: www.fda.gov/cder/drug/infopage/vioxx/PHA_vioxx.htm

  • Fosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, Sørensen R, Rasmussen JN, Andersen SS, Abildstrom SZ, Traerup J, Poulsen HE, Rasmussen S, Kober L, Torp-Pedersen C (2009): Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: A nationwide cohort study. Clin Pharmacol Ther 85: 190–19

    Article  Google Scholar 

  • Fu JY, Masferrer JL, Seibert K, Raz A, Needlemam P (1990): The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 265: 16737–16740

    PubMed  Google Scholar 

  • Gemeinsamer Bundesausschuss (2012): Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses über die Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III Nummer 18 – Antiphlogistika oder Antirheumatika in fixer Kombination mit anderen Wirkstoffen vom 22. November 2012. Internet: http://www.g-ba.de/downloads/40-268-2120/2012-11-22_AM-RL3_Nr18-Antirheumatika_TrG.pdf

  • Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA (2005): Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475–481

    Article  PubMed  Google Scholar 

  • Graham DY, White RH, Moreland LW, Schubert TT, Katz R, Jaszewski R, Tindall E, Triadafilopoulos G, Stromatt SC, Teoh LS (1993): Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group. Ann Intern Med 119: 257–262

    Article  PubMed  Google Scholar 

  • Gretzer B, Ehrlich K, Maricic N, Lambrecht N, Respondek M, Peskar BM (1998): Selective cyclo- oxygenase 2 inhibitors and their influence on the protective effect of a mild irritant in the rat stomach. Brit J Pharmacol 123: 927–935

    Article  Google Scholar 

  • Hawkey CJ (1999): COX-2 inhibitors. Lancet 353: 307–314

    Article  PubMed  Google Scholar 

  • Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E et al (2000): Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 43: 370–377

    Article  PubMed  Google Scholar 

  • Hernández-Diaz S, Varas-Lorenzo C, Garcia Rodríguez LA (2006): Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98: 266–274

    Article  PubMed  Google Scholar 

  • Jüni P, Rutjes AWS, Dieppe PA (2002): Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Brit Med J 324: 1287–1288

    Article  PubMed Central  PubMed  Google Scholar 

  • Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL (2005): Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 142: 157–164

    Article  PubMed  Google Scholar 

  • Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H et al (1999): A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 117: 776–783

    Article  PubMed  Google Scholar 

  • Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD Logan RF, Murphy M, Vessey MP, Colin-Jones DG (1994): Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 323: 1075–1052

    Google Scholar 

  • Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H et al (1999): Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDS. JAMA 282: 1929–1933

    Article  PubMed  Google Scholar 

  • Lin J, Zhang W, Jones A, Doherty M (2004): Efficacy of topical non-steroidal antiinflammatory drugs in the treatment of osteoarthritis: metaanalysis of randomised controlled trials. Brit med J 329: 324–326

    Google Scholar 

  • Mc Gettigan P, Henry D (2006): Cardiovascular risk and inhibition of cyclooxygenase: a systemic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1633–1644

    Google Scholar 

  • Meyer R (2005): Pfizer nimmt Bextra vom Markt. Dtsch Ärztebl 102: A 1023

    Google Scholar 

  • Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR (1993): Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90: 11693–11697

    Article  PubMed Central  PubMed  Google Scholar 

  • Mukherjee D, Nissen SE, Topol EJ (2001): Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954–959

    Article  PubMed  Google Scholar 

  • Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM (2005): Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091

    Article  PubMed  Google Scholar 

  • Patel AM, Moreland LW (2010): Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 4: 263–278

    PubMed Central  PubMed  Google Scholar 

  • Peskar BM, Maricic N, Gretzera B, Schuligoi B, Schmassmann A (2001): Role of cyclooxygenase- 2 in gastric mucosal defense. Life Sci 69: 2993–3003

    Article  PubMed  Google Scholar 

  • Piroxicam Rote-Hand-Brief (2007): Neue Anwendungsbeschränkungen für die systemische Anwendung von Piroxicam aufgrund gastrointestinaler Nebenwirkungen und Hautreaktionen. Internet: www.akdae.de/20/40/Archiv/2007/40-20071011.pdf

    Google Scholar 

  • Prescrire international 2010: Rheumatoid arthritis: choice of antirheumatic treatment. Prescrire international 19: 30–34

    Google Scholar 

  • Psaty BM, Kronmal RA (2008): Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment. A case study based on documents from rofecoxib litigation. JAMA 299: 1813–1817

    PubMed  Google Scholar 

  • Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G, Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Haim M, Reginster JY (2004): Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach. Ann Rheum Dis 63: 759–766

    Article  PubMed Central  PubMed  Google Scholar 

  • Ross JS, Hill KP, Egilman DS, Krumholz HM (2008): Guest authorship and ghostwriting in publications related to rofecoxib. A case study of industry documents from rofecoxib litigation. JAMA 299: 1800–1812

    PubMed  Google Scholar 

  • Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, Folke F, Charlot M, Selmer C, Lamberts M, Bjerring Olesen J, Køber L, Hansen PR, Torp-Petersen C, Gislason GH (2011): Duration of treatment with nonsteroidal anti-inflammatory drugs and impact of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 123: 2226–2235

    Article  PubMed  Google Scholar 

  • Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ; TARGET Study Group (2004): Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665–674

    Google Scholar 

  • Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K (2010a): Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen. Teil 1. Dtsch Ärztebl 107: 279–285

    Google Scholar 

  • Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD (2010b): Finanzierung von Arzneimittelstudien durch pharmazeutische Unternehmen und die Folgen. Teil 2. Dtsch Ärztebl 107: 295–301

    Google Scholar 

  • Shi S, Klotz U (2008): Clinical use and pharmacological properties of selective COX-2 inhibitors. Eur J Clin Pharmacol 64: 233–252

    PubMed  Google Scholar 

  • Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. (2000): Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 284: 1247–1255

    Article  PubMed  Google Scholar 

  • Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, Meyer J, Paulding CA (2010): A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 42: 711–714

    Article  PubMed  Google Scholar 

  • Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014): EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73: 492–509

    PubMed Central  PubMed  Google Scholar 

  • Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M; Adenoma Prevention with Celecoxib (APC) Study Investigators (2005): Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080

    PubMed  Google Scholar 

  • Solomon DH, Schneeweiss S, Glynn RJ, Kiota Y, Levin R, Mogun H, Avorn J (2004): Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068–2073

    Article  PubMed  Google Scholar 

  • Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P (2011): Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta- analysis. Brit Med J 342: c 7086 1–11

    Google Scholar 

  • Vane JR (1971): Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232–235

    Article  PubMed  Google Scholar 

  • Wolfe MM, Lichtenstein DR, Singh G (1999): Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888–1899

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 20246, Hamburg

    Prof. Dr. med. Rainer H. Böger

  2. Institut für Pharmakologie und Toxikologie, Universität, Robert-Koch-Straße 40, 37075, Göttingen

    Prof. Dr. med. Gerhard Schmidt

Authors
  1. Prof. Dr. med. Rainer H. Böger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gerhard Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

H. Böger, R., Schmidt, G. (2014). Antirheumatika und Antiphlogistika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs- Report 2014. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43487-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-43487-1_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43486-4

  • Online ISBN: 978-3-662-43487-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation